Is Bayer's Improved Earnings and KERENDIA Progress Shifting the Investment Case for Bayer (XTRA:BAYN)?

• Bayer reported third quarter 2025 earnings, showing sales of €9.66 billion and a net loss of €963 million, a significant improvement from a much larger net loss last year, while also presenting positive late-stage clinical data for its kidney disease drug KERENDIA.
• Alongside financial improvements, Bayer's ongoing pipeline progress, highlighted by KERENDIA's latest Phase III trial results, signals continued momentum in bringing innovative treatments to market despite industry challenges.
• We'll examine how Bayer's return to profitability in the year-to-date period and advancement of its KERENDIA program affect the investment narrative.

We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Bayer Investment Narrative Recap

To hold Bayer stock, investors need confidence in the company's long-term ability to deliver both scientific innovation and stable earnings, despite near-term headwinds. The latest quarterly results show meaningful progress with a reduced net loss and strengthening pharma pipeline, yet do not resolve the material overhang from unresolved litigation, still the single biggest risk to short-term cash flow and sentiment. While improving operational results are encouraging, they have not eliminated this fundamental uncertainty.

The most relevant recent announcement is Bayer's release of new positive late-stage clinical results for KERENDIA in patients with diabetes and kidney disease. This progress directly addresses investor focus on pipeline execution and future revenue streams, potentially offsetting headwinds from pricing pressure or upcoming patent expirations. These updates lend support to the view that late-stage assets can help replace revenue at risk from older, mature products.

In sharp contrast, unresolved legal exposures remain a significant variable investors need to keep in mind if considering the stock...

Read the full narrative on Bayer (it's free!)

Bayer's narrative projects €48.0 billion in revenue and €3.1 billion in earnings by 2028. This reflects a 1.3% annual revenue growth rate and a €6.5 billion increase in earnings from the current level of €-3.4 billion.

Uncover how Bayer's forecasts yield a €28.53 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members offered 13 separate fair value estimates for Bayer, ranging widely from €28.53 to €174.48 per share. While many see value, market participants are closely monitoring how legal challenges could continue to pressure cash flows and affect future performance.

Explore 13 other fair value estimates on Bayer - why the stock might be worth just €28.53!

Build Your Own Bayer Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Bayer research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Bayer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bayer's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com